van der Pol, Karel H.
Aljofan, Mohamad
Blin, Olivier
Cornel, Jan H.
Rongen, Gerard A.
Woestelandt, Aurélie-Gaëlle
Spedding, Michael
Article History
Accepted: 17 May 2023
First Online: 3 July 2023
Declarations
:
: No specific funding was obtained for the writing of this article.
: MSP is developing ambroxol for use in amyotrophic lateral sclerosis. OB is a stakeholder of Thelonious Mind. JHC has received grants from Novo Nordisk and Stichting Vaatresearch not related to the current work and has received advisory board fees from Amgen. All other authors declare no competing interests.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors substantially contributed to the work. All authors jointly conceptualised the current work. KP wrote the initial draft and edited it after review. All authors reviewed the initial draft and contributed to the reviewed draft.